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Abstract
In 2018,  the International  Council  for Standardization in Hematology (ICSH) published a consensus
document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since
that publication, several significant changes related to DOACs have occurred, including the approval of
a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent
intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to












































































recognized  areas  where  additional  information  was  warranted,  including  patient  population
considerations and updates in point-of-care testing. The information in this manuscript supplements
our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on
(1)  information  from  peer-reviewed  publications  about  laboratory  measurement  of  DOACs,  (2)
contributing author’s personal experience/expert opinion and (3) good laboratory practice.
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Introduction
In 2018,  the International  Council  for Standardization in Hematology (ICSH) published a consensus
document  providing guidance for  laboratories on measuring direct  oral  anticoagulants  (DOACs).[1]
Since  that  publication,  several  significant  changes  related  to  DOACs have  occurred,  including the
approval of a specific DOAC reversal agent (intended for use when the reversal of anticoagulation with
apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding), andexanet alfa
(Andexxa®  in  the  US,  Ondexxya  in  the  EU)  from  Portola  Pharmaceuticals  Inc.[2,  3] Betrixaban
(Beyvexxa®, Portola), the fourth direct factor Xa DOAC was approved for use in the United States but
has since been discontinued by the manufacturer and will not be addressed. In addition, this ICSH
Working  Party  recognized  areas  where  additional  information  was  warranted,  including  patient
population  considerations  and  updates  in  point-of-care  testing  (POCT).  The  information  in  this
manuscript supplements our previous ICSH DOAC laboratory guidance document.[1] The consensus
recommendations  provided  are  based  on  (1)  information  from  peer-reviewed  publications  about
laboratory measurement of DOACs, (2) contributing author’s personal experience/expert opinion and
(3) good laboratory practice.
Patient selection for DOAC testing
As with the first ICSH DOAC publication, whether or not patients should be tested is beyond the scope
of  this  document.[1,  4-6] However,  laboratory  staff  should  be  aware  of  emerging  publications
conveying potential advantages of measuring DOAC level (Table 1). In addition to previously indicated
clinical situations (usually urgent situations) where DOAC measurements may be useful [1, 6] evidence
is accumulating between drug exposure and clinical outcome.[7-11] Additional data, albeit low grade,
may support other situations and patients that may benefit from DOAC assessment.[12, 13] Included












































































as patients with acute bleeding, in order to determine appropriate reversal strategies and associated
dosing required.[17-19] Some have also suggested DOAC measurements in patients the day prior to
undergoing  interventions  with  high  bleeding  risk  (e.g.  complex  endoscopy,  spinal  or  epidural
anesthesia, thoracic surgery, abdominal surgery, major orthopedic surgery or neurosurgery)  [5, 20-
23], although it should be noted that this approach of measuring DOACs is currently not supported by
clinical evidence and the relevance of the current threshold is questioned.[24] Specifically, although
the “Perioperative Anticoagulant Use for Surgery Evaluation study” (PAUSE) trial reported acceptable
bleeding rates with their clinically defined anticoagulant interruption strategies and defined thresholds,
i.e. analyses were done for residual DOAC levels ≥30 ng/mL and ≥50 ng/mL,[25, 26] it is not known
what DOAC level would be considered “safe” to undergo a surgical procedure or intervention and with
the vast majority of patients,  a time-wait period appears to be safe.[25,  26] With limited data on
patients with a body mass index (BMI) >40 kg/m2, DOAC pharmacokinetic and/or pharmacodynamics
measurements in this population may be considered.[27, 28] In addition, many elderly patients with
non-valvular atrial fibrillation may acutely develop decompensated heart insufficiency with increase of
liver enzymes, decreased intestinal blood flow and develop an unpredictable pharmacokinetic profile
which may lead to an increased bleeding risk. DOAC measurements may be useful in detecting DOAC
overexposure and bleeding risk; DOAC underexposure and thrombotic risk; and identifying previously
undescribed  and  described  drug-drug  interactions,  although  this  needs  to  be  confirmed  in  larger
cohorts.[29-31] It should be noted that pediatric patients may have lower DOAC levels than  adults
[32], and modifications of anti-Xa methods may be required. In addition, discrete age-partitioned and
age-appropriate reference intervals are likely needed for coagulation test in the pediatric population.
[33]
Consensus recommendations
o This  ICSH  Working  Party  recognizes  there  is  insufficient  data  to  date  for  providing  dose-
adjustment  recommendations  based  on  DOAC  levels  alone.  Nevertheless,  DOAC
measurements may identify potential excessive clearance or drug accumulation and could be
used in situations where the benefit of such measurement is likely to outweigh the risk, e.g. in
non-urgent situations.
o Several categories of patients may benefit from DOAC level measurements to ensure they are













































































o If a DOAC measurement has been requested for urgent purpose, results should be provided
within 30 minutes to aid in acute clinical decision-making.
o This ICSH Working Party encourages laboratories to provide DOAC measurements per clinical
need. DOAC results must be used (and interpreted) in the context of patient history, DOAC
type,  DOAC  dose,  last  dose,  and  potential  impact  on  clinical  management  (e.g.  surgical
intervention, bleeding, reversal strategies).
DOAC and laboratory testing
The first ICSH laboratory DOAC guidance document already detailed test procedures or methods for
quantifying  DOACs  such  as  the  ecarin  clotting  time  (ECT),  dilute  thrombin  time  (dTT)  or  anti-Xa
measurements.[1] More methodological details can also be found elsewhere.[34-36] Of particular note,
the ECT used in the dabigatran trials, and ECT range cited in prescriber information is based on an ECT
reagent concentration of 6 IU/mL.[35] 
Interference of DOAC on coagulation assays
It  has  been  widely  shown that  DOACs may interfere  with  coagulation  testing,  even  at  low DOAC
concentrations.[37] Thus,  even trough collections  aimed to  minimize  DOAC concentration  may be
inadequate to completely eliminate drug interference in certain assays.[37] To ensure an undetectable
DOAC concentration,  a delay of  3  days  or  more (dependent  on DOAC,  renal  function  and clinical
situations) between the last intake and testing could be necessary. A longer delay is likely necessary
for lupus anticoagulant (LA) testing with dRVVT tests, due to the interference that may still be present
when DOAC concentration is below the lower limit of quantification of the anti-Xa based method (anti-
Xa). However, due to high inter-individual DOAC variability and potential thrombotic risk, a wait period
of 3 days may not be a suitable alternative unless bridging therapy (e.g. low molecular weight heparin)
is considered.[38] Alternatively, in vitro removal of DOAC compounds from plasma prior to coagulation
testing has been reported and may be more suitable.[39-47] DOAC-Stop® (adsorbing agent, Hematex
Research,  Australia)  and  DOAC-Remove®  (activated  carbon,  5-Diagnostics,  Switzerland),  both
reportedly able to neutralize all DOACs with minimal effect on hemostasis tests, have been recently
commercialized.[39-47] However, care should be taken, especially in LA testing, since in the reported
studies,  complete reversal  did not occur  in  every sample and reversal  varies among the different
DOACS.[42, 43, 45, 48, 49] Some differential effects may be observed between use of DOAC-Stop® vs.












































































Additionally,  a  slight  procoagulant  effect  of  DOAC-Stop® has  been  shown in  thrombin  generation
assays that use an intermediate concentration of tissue factor (i.e. around  5 pM). This procoagulant
effect seems to be related to slight reduction in tissue factor pathway inhibitor (TFPI).[50, 51] The
elimination of DOAC presence in plasma using filters like the DP-Filter (5-Diagnostics) or the DOAC-
Filter (Diagnostica Stago, France)  showed promising results.[39, 52] However, potential  unintended
filtration of coagulation proteins seen with other filtering mechanisms (e.g. von Willebrand factor) may
occur but the interference of DOAC-Stop® or DOAC-Remove® on these other coagulation proteins has
also been found (e.g. interference on TFPI), impacting mainly thrombin generation assays (TGA).[51]
Lastly, new products are currently under evaluation that demonstrates low to no DOAC interference for
LA detection.[53, 54]
Interference of DOAC on platelet aggregation and fibrinolysis assays
Sokol et al. demonstrated a reduction in thrombin-induced platelet aggregation with rivaroxaban and
apixaban,  a  result  different  from a  previous  investigation  with  rivaroxaban.[55,  56] This  requires
further investigations and confirmations. As expected, a similar effect has been reported by Shimizu et
al. with dabigatran.[57] However, the interference with platelet aggregation is most likely an indirect
effect of DOACs driven by the inhibition of thrombin generation.[58] Additionally, it has been shown
that dabigatran, rivaroxaban, and apixaban enhance fibrinolysis but this depends on the presence of
thrombomodulin in the test system.[59-62] As such, caution should be used when performing and
interpreting the results from any coagulation-related test from a DOAC treated patient.[37]
Management of heparin bridging in DOAC treated patients
DOAC treated patients may suffer an acute event that requires bridging with UFH or LMWH. For UFH
bridging of dabigatran, only the anti-Xa activity should be considered suitable to measure UFH effect,
as APTT and (dilute) thrombin time will be prolonged by both drugs.[63] In the case of direct factor Xa
inhibitors, alternatives to APTT or anti-Xa measurements are required, since both anticoagulant types
affect  these tests,  leading to supra-therapeutic  anti-Xa values.[64] Testing options to address this
could include 1) an UFH calibrated thrombin time test or 2) neutralizing the DOAC effect in vitro using
aforementioned neutralizing products. In studies using drug enriched plasma, DOAC-Stop® extracts
DOACs efficiently with no effect on heparin-type anticoagulants, but it binds argatroban and hirudin-
type anticoagulants.[45] To date,  data on the efficacy of  UFH monitoring in the presence of  such
compounds or using thrombin time calibration curve are lacking.












































































Global tests such as the thrombin generation assay (TGA) have been described as promising to assess
the pharmacodynamic profile of anticoagulants.[65, 66] Given the known DOAC thrombin generation
profiles,  the  concentration  thresholds  proposed  in  the  literature  may  provide  highly  different
anticoagulant activities in a particular patient and TGA may be seen as another way of expressing and
assessing  the  degree  of  anticoagulation  in  DOAC treated  patients  (Figure  2).[24,  66-71] The  ST
Genesia (Diagnostica Stago, Asnières sur Seine Cedex, France), an automated analyzer for thrombin
generation  testing has the potential  for a wide implementation in routine laboratories.  Preliminary
observations  showed  that  thrombin  generation  testing  is  affected  by  all  anticoagulant  drugs,
suggesting  that  this  assay  could  be  useful  in  assessing  DOAC activity,  but  this  deserves  further
confirmation in larger cohorts  to validate this  approach since to date,  the role of  TGA for clinical
decision-making in DOAC-treated patients is not clear.[68, 70-72]
Limitations of Laboratory Testing
Previously, the ICSH DOAC Working Party provided provisional guidance for the effect of DOACs on
commonly  ordered  coagulation  assays.[1] The  limitations  for  assessing  DOAC  presence,
pharmacokinetics or pharmacodynamics using screening or global assays, or other coagulation tests
are  still  present,  although  the  use  of  neutralizing  systems  appear  promising.  DOAC  neutralizing
systems have not been fully evaluated for all tests or test platforms and their use and interpretations
must  employ  a  degree  of  caution.[1] Local  verification  of  in  vitro  neutralizing  agents  (activated
charcoal or filters) to assure 1) adequate DOAC neutralization by using sensitive techniques and 2) no
deleterious effect on the test method is required prior to clinical use.
Consensus recommendations
o Caution should be used when performing and interpreting the results from any coagulation test
result from a DOAC treated patient.
o In vitro use of DOAC neutralizing agents must be used with caution and must be locally verified
prior to clinical use.
o Select  thrombophilia  test  methods  (e.g.  clot-based  measurement  of  protein  C  or  lupus
anticoagulant) can show interference at low DOAC concentrations. Use of DOAC neutralizing
products  may  not  completely  achieve  DOAC reversal  thus  results  from some assays  may












































































o DOAC removal  systems appear  to be a suitable in  vitro means of  neutralizing DOAC from
plasma to minimize drug interference in coagulation testing, although it is unclear whether
these DOAC removal systems are interchangeable with DOAC neutralization products.
o Laboratories  should  have  a  procedure  for  adequately  assessing  and  differentiating
anticoagulation effect when bridging therapy is required.
o While  preliminary  results  are  encouraging,  there  is  currently  no  sufficient  evidence  to
recommend thrombin generation assays to guide clinical decisions in a DOAC-treated patient.
o Laboratories should be aware of limitations of laboratory testing for DOAC measurements and/
or effect of DOACs on coagulation assays.
DOAC reversal agents
Andexanet alfa
Since the initial publication of the guidance, a specific reversal agent, andexanet alfa was approved in
the US for rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening
or uncontrolled bleeding, and has  also been approved by the Committee for Medicinal Products for
Human Use in Europe for the same application.[3, 73] There are two dosing strategies (low and high
dose), as a bolus followed by a continuous infusion. This reversal agent will reduce the levels of direct
factor Xa inhibitors, as measured by calibrated chromogenic anti-Xa activity.[74] There is a transient
rise in prothrombin F1+2 fragments and D-dimer value after andexanet alfa is given, and an increase
in thrombin generation, which may be related to the observed concomitant TFPI inhibition.[2, 3, 75,
76] Whether this observation is due to the inhibition of TFPI or whether it is clinically important is not
yet known and deserves some caution.
Idarucizumab
Idarucizumab is a specific reversal agent for dabigatran and is indicated in adult dabigatran etexilate
treated patients with dabigatran etexilate when rapid reversal of its anticoagulant effects is required
such as in emergency surgery or urgent procedures and in life-threatening or uncontrolled bleeding. It
has been approved for the same indications in both US and Europe based on the results from the
REVERSE-AD study which showed the efficacy and safety of idarucizumab to reverse the anticoagulant
effect  of  dabigatran  in  dabigatran-treated  patients  who  experienced  serious  bleeding  or  required
urgent invasive procedures.[77-79] Although the product has been on the market for more than 3












































































setting.[80-84] No specific dabigatran monitoring is currently recommended before reversal or during
follow-up according to the prescribing information as approved by the regulatory authorities.[77, 78]
DOAC reversal agents and the laboratory
As  andexanet alfa  reduces  the  DOAC  level  after  bolus  and/or  infusion,  but  DOAC  levels  recover
following  cessation  of  infusion,  it  can  be  speculated  that  post-infusion  coagulation  tests  may  be
affected (for rivaroxaban, the residual drug level after  andexanet alfa treatment was approximately
40% from pretreatment levels, a concentration that can still affect coagulation tests).[85] Evaluating
post-infusion  rivaroxaban  or  apixaban  anti-Xa  measurements  is  not  supported  by  current  FDA
recommendations as they indicate that the likelihood of using anti-FXa activity as a surrogate endpoint
to  predict  a  clinical  benefit  of  hemostasis  is  not  evident.[3] However,  pretreatment  DOAC
measurements may be warranted [86] to determine whether the low or high dose regimen should be
used, as well as providing the potential to avoid unnecessary patient exposure to reversal antidotes.
[87] However, this cannot be detrimental to the patients and should not delay the administration of
reversal agents, especially in DOAC-treated patients with life-threatening bleeding, such as intracranial
bleeding or in those requiring emergency surgery for life-threatening conditions such as a ruptured
aortic aneurysm. In such context,  rapid POC device with appropriate clinical  performance is highly
needed to guide the best strategy for patient’s management.
It should be noted that the current dosing recommendations of andexanet alfa are based on both the
dose and the time since the last intake of apixaban and rivaroxaban.[2, 3] However, in an unconscious
patient,  such  information  cannot  always  be  obtained.  The  plasma  concentration  of  apixaban  or
rivaroxaban could be of interest in this context, but the definition of specific thresholds based on these
plasma concentrations at the time of the admission is not yet available. Otherwise, specific tests are
required  in  the  unconscious  patient  to  discriminate  between  the  type  of  anticoagulant  (IIa  or  Xa
inhibitor) and could be useful to follow the efficacy of andexanet alfa administration. Several point-of-
care devices are currently under investigation that may prove useful in this setting (see the section on
point-of-care  device  below).  Importantly,  commercially  available  anti-FXa  assays  measure  FXa
inhibitors  using drug  specific  calibrators  and  controls.  However,  there  are  limitations  when  these
assays are used for measuring DOAC concentration in andexanet alfa patient samples. One of the
limitations is the large sample dilution in the assay setup, which causes dissociation of the inhibitor
from the andexanet alfa-inhibitor complex (due to the reversible binding equilibrium of the andexanet












































































administration.  Therefore,  some anti-Xa assays may have to be modified in order to be utilized if
chromogenic anti-Xa assays are used to evaluate the degree of reversal of andexanet alfa.[88]
For dabigatran reversal, a single dose of idarucizumab (Praxbind®, Boehringer Ingelheim) will bind up
to 1,000 ng/mL of the drug, but there appears to be a rebound or dissociation effect after 12-24 hours.
As such, measurements of  dabigatran may predict  the need for secondary dosing of  this reversal
agent.[19] In a retrospective study, it has been shown that the assessment of dabigatran levels before
introducing the reversal therapy could predict the hemostasis effectiveness and the potential rebound
in dabigatran levels after idarucizumab injection and that specific dabigatran threshold (i.e. 264 ng/mL
as reported in this study) may be of interest to predict hemostatic ineffectiveness, dabigatran rebound,
and outcomes after reversal.[80] Idarucizumab has no known impact on coagulation parameters by
itself.
Other  agents  that  have been  used for  DOAC reversal  include 3  or  4  factor  prothrombin  complex
concentrates  (PCCs) or activated PCCs.[89-94] These non-specific reversal  agents are expected to
have an impact on coagulation screening tests but not on anti-Xa or anti-IIa based assays, but data are
currently limited with DOAC reversal  strategies.  The amount of PCC needed to stop DOAC-induced
bleeding  may  depend  on  the  residual  DOAC-concentration  at  the  time  PCC  is  administered.[95]
However, while clinical bleeding may be sufficiently controlled with a single dose of PCC, the impact of
DOAC on some laboratory tests may not be completely abolished as the relationship between residual
DOAC level  as  measured  by  laboratory  testing  and the  risk  of  uncontrolled  bleeding  is  currently
unclear.[18]
Consensus recommendations
o For andexanet alfa, due to its pharmacodynamic profile, the use of anti-Xa techniques for the
evaluation of post-infusion rivaroxaban or apixaban anti-Xa activity is not supported.
o Post-andexanet alfa treatment testing of apixaban and rivaroxaban concentrations is affected
by anti-Xa methods that use high sample pre-dilutions causing factitiously elevated FXa DOAC
results.
o For idarucizumab, measurements of dabigatran may predict the need for secondary dosing of
this  reversal  agent  since  the  presence  of  idarucizumab  does  not  seem  to  interfere  with
dabigatran.
o  How  to  best  assess  the  reversal  efficacy  of  specific  antidotes  (i.e.  andexanet  alfa  or












































































o PCCs administration should not be monitored by measurement of DOAC concentrations that
will not be modified.
o Assessment  of  DOAC  reversal  by  global  or  specialized  laboratory  assays  are  method
dependent and may be misleading.
DOAC Point-of-Care Testing (POCT)
The widespread  use of  DOACs and  the need  for  urgent  determination  in  aforementioned  specific
clinical situations has spurred several investigators and manufacturers to pursue POCT technologies
for  measuring  (or  quantifying)  DOAC  anticoagulant  effect.[96-98] Included  are  microfluidic
technologies  [98-101] and surface acoustic waves (SAWs) technologies.[102] While the preliminary
findings are promising, shortcomings include use of an animal model,[101] or in vitro enriched DOAC
blood,[99] data from a small series of patients,[99, 100] and only a limited number of DOACs assessed.
[99,  101,  102] In  addition,  these  methods  appear  to  be  several  years  from  actual  clinical
implementation, as none have undergone the rigors of in vitro device (IVD) clinical trials. 
The TEG 6S NOAC assay is  a  cartridge  currently  undergoing clinical  trials  which  can be used for
qualitative DOAC assessment.[103-105] The 4 channels, single-use NOAC cartridge contains kaolin in
channel 1, ecarin in channel 2, factor Xa in channel 3, and abciximab in channel 4, with channels 2 and
3 providing differentiation in DOAC effect of prolonged clotting times. In a small series of patients
receiving dabigatran, rivaroxaban, or apixaban, the ROC analysis yielded a sensitivity of 94% and 92%
for  channel  2  (dabigatran)  and  channel  3  (direct  FXa inhibitors)  respectively.[105] Since  the  last
publication,[1] Harenberg  et  al. published  recommendations  regarding  the use of  a  urine dipstick
device which  was shown to be sensitive and specific to determine the presence of both Xa and IIa
inhibitors in urine samples. The evaluation of the DOAC Dipstick test in emergency medicine and other
patient groups is currently ongoing. This device allows qualitative determination of direct thrombin or
factor Xa inhibitors and  may aid in generating algorithms for clinical decision-making in a bleeding
patient or for a patient requiring urgent surgical intervention in conjunction with laboratory plasma-
based assays.[106, 107] However, cautious and informed use of this urine DOAC screening method is
required, as there is no direct relationship between plasma and urine DOAC concentrations despite the
excellent sensitivity and specificity of the device. In any case, if DOAC is detected in the urine by the













































































While not specifically  a POCT, dried blood spot (DBS) technology may be a suitable alternative to
traditional blood collection for non-emergent assessment of DOACs.[98, 108] This method would allow
for at home collection using fingers stick blood collection onto filter paper, which is then sent via postal
service to a laboratory that can provide a quantitative DOAC levels determination using tandem mass
spectrometry. However, it must be emphasized that mass spectrometry testing using DBS must also
be  validated  using  DBS  collected  samples. In  addition,  the  hematocrit  level  of  blood  may  cause
systematic bias in analyte measurement in DBS samples, and it is also a practical challenge to train
and  ensure  appropriate  DBS  collection  procedures  being  carried  out  by  in  home  patients  since
inappropriate  DBS  collection  can  cause  significant  variability  in  assay  measurement.  However,
volumetric absorptive microsampling (VAMS), a recent microsampling technique used to obtain dried
specimens  of  blood promises to bring some significant  advantages  over DBS, related to sampling
volume accuracy,  hematocrit  (HCT) dependence, pretreatment and automation.[109] We also must
emphasize that the lack of availability of LC-MS/MS in smaller laboratories, the long turnaround time,
the  cost  and  the  labor-intensive  sample  preparation  restrict  the  use  of  this  strategy  in  most
laboratories.  However,  if  the  testing  is  not  urgent,  the  VAMS collection  device  can  be  sent  to  a
reference laboratory which can provide standardized and validated DOAC analyses overcoming the
potential geographical limitations.[110]
Consensus recommendations
o Tests and technologies of various POCT devices may provide totally different type of results.
o Global coagulation POCT like SAWs and thromboelastometry are promising for identifying the
drug on board but their usefulness to evaluate the degree of anticoagulation is still unclear and
further investigations are warranted.  
o Rapid  urine  testing  may  rapidly  identify  the  DOAC  type  taken  which  may  assist  clinical
decision-making.
o DBS  and  VAMS  technology  may  be  of  interest  to  perform  pharmacokinetic  investigations
without suffering from geographical limitations and rapid access to specialized laboratories.
External Quality Control (EQA)
Most international EQA programs now have established EQA exercises for DOACs and demonstrate a
wide implementation of specific DOAC testing in certain regions of the world.[111-118] Nevertheless,












































































drug measurements may be limited to specialized laboratories. In addition, only few undertake the in-
house  validation  of  these  techniques  refraining  the  clinicians  to  ask  for  these  specific  drug
measurements.  This  is  detrimental  to  the  patients,  especially  knowing  the  limitations  of  routine
coagulation  tests  for  DOAC  testing  which  are  used  instead.  These  routine  tests  showed  a  poor
analytical and clinical performance in the different clinical settings where DOAC measurement may be
beneficial.[6, 119]
Some  international  EQA  programs  have  also  undertaken  and  published  studies  looking  at  DOAC
interference in hemostasis tests,[111-118] as well as undertaken studies looking at neutralizing the
interference of DOACs in hemostasis tests.[120] Although differences were seen between the various
methodologies, reliable and reproducible DOAC levels were measured overall. A five-year overview of
experience for the quality performance of DOACs over a large concentration range showed a good
correlation between the different methodologies. Although no international calibration standards were
available,  the  overall  CVs  were  small  for  dabigatran,  rivaroxaban  and  apixaban,  and  were  also
comparable to the CVs (range 3– 14%) for the International Normalized Ratio derived from the same
years.[113] 
The outcome for the various methodologies in the EQA surveys could be used to establish clinical
decision  rules adapted for  specific reagents.  This is  especially  relevant  in  the ranges approaching
clinical  decision  limits. Laboratories  are  strongly  encouraged  to  participate  in  EQA  programs  that
adequately  address  the  pharmacodynamics  and  pharmacokinetics  of  DOACs,  as  well  as  the
identification of DOAC sources of interference in other coagulation assays.
Consensus recommendations
o Laboratories are strongly encouraged to participate in EQA programs that assess DOAC effects
on  screening  tests  and  quantitative  measurements,  as  well  as  their  interference  in  other
coagulation assays.
o Collecting  information  on  DOAC  testing  availability  and  performance  around  the  world  is
necessary in order to help various Working Parties provide guidelines.
Future Perspectives
The emergence of DOACs and their increased use, as well as the introduction of anticoagulants in
future will provide a challenge for clinical laboratories. It is likely that DOAC use will increase as clinical












































































demonstrated non-inferiority to standard care treatment.[121] Rivaroxaban use in pediatric patients
(Einstein-Jr clinical trial, NCT02234843) is completed and awaiting approval for use in cerebral venous
thrombosis  [122] and catheter-related VTE.[123] Summary of the use of rivaroxaban in the pediatric
population is also available elsewhere.[124] Apixaban is being evaluated in VTE reduction in pediatric
patients  with  congenital  heart  disease  [125] and acute  lymphoblastic.[126] Edoxaban  is  currently
under investigation for use in pediatric patients at risk for thromboembolic complications due to heart
disease  (www.clinicaltrials.gov;  NCT 03395639).  Other  DOAC  clinical  trials  include  use  for  VTE
prevention  in  patients  with  cancer  (clinicaltrials.gov;  NCT03240120;  NCT03692065),  post  bariatric
surgery  (clinicaltrials.gov;  NCT03522259;  NCT02406885),  SARS-CoV-2  infections  (clinicaltrials.gov;
NCT04757857; NCT04650087; NCT04542408) and others will likely increase the use of DOACs once
efficacy has been established.
In addition  to the increase use of  DOACs in multiple  settings with unclear  expected “on-therapy”
ranges and drug detection requirements, other technical considerations and concerns for the clinical
laboratory would be the other anticoagulants under investigation.[127] As these drugs effect in-vivo
anticoagulation,  it  is  likely their  ex-vivo effect will  also likely add another layer of complexity and
concern for the clinical coagulation laboratory. The hope and promise of POC methods with increased
sensitivity and specificity for novel anticoagulants, including DOACs, may alleviate some burden on the
laboratory.
What is known:
- Direct oral anticoagulants are used worldwide for several thromboembolic indications.
- the 2018 ICSH document provided hemostasis-related guidance for clinical laboratories.
- This document addressed all phases of laboratory DOAC measurements.
What does this paper add?
- This guidance updates the 2018 edition with a particular focus on antidotes, point-of-care testing
(POCT) and global coagulation tests
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Figure 1:  Laboratory  testing for  DOAC and expected plasma concentrations  after  therapeutic
doses. Orange boxes represent ranges of applicability of the corresponding test. Dashed orange
boxes represent the zone in which the variability may change due to different reagent sensitivities.
Note that only reagents considered as sensitive/reactive were considered. Plasma concentration
ranges are extracted from the European Summary of Product of Characteristics for all indications
of apixaban (reference [128]) and dabigatran (reference [129]) and for VTE and ACS indications of
rivaroxaban (reference  [130]), from Mueck  et al. for rivaroxaban in NVAF (reference  [131]), and
from Ruff  et al. (reference  [7]),  Weitz  et al. (reference  [132]) and Verhamme  et al. (reference
[133]) for edoxaban.
APTT,  activated  partial  thromboplastin  time;  CMAX,  maximum plasma  concentration  during  the
dosing interval;  CTROUGH, minimum plasma concentration during the dosing interval;  dTT, diluted
Thrombin Time; ECA, ecarin chromogenic assay; IQR, interquartile range; NVAF, non-valvular atrial
fibrillation; PT, prothrombin time; TT, thrombin time; VTE, venous thromboembolism. 
Figure  2:  The  thrombogram  parameters  from  thrombin  generation  test  and  representative
changes at relevant concentrations of DOACs. Note: Thrombin generation was triggered by 5pM
tissue  factor  with  4µM phospholipids  in  absence  of  exogenous  thrombomodulin  or  exogenous
activated protein C.
Table  1:  Indication  for  testing  of  direct  oral  anticoagulants  according  to  level  of


















































































Increase rate  of  bleeding  events  with  age
and  increased  susceptibility  of  bleeding
events with DOAC accumulation.
If  done,  plasma  DOAC
concentrations should be
measured a trough, just
before  the  next  pill  or
capsule intake after 5 or
more  intake  to  ensure
the  DOAC  has  reached
its steady state.
Plasma  DOAC
concentration  should  be
in  the  range  of
concentrations  observed
in other populations.
Post-hoc  analyses  of  safety
outcome  from  phase-3
clinical  trials  and  post-
marketing  observational
studies. 
NB: Data are lacking to show
the  benefit  of  adjusting  the
dose based on individual PK
evaluation,  but  these  data
suggest  that  the  optimal





Increase  levels  of  DOAC  reflected  by
increased  CMAX and  AUC,  especially  for
dabigatran,  rivaroxaban  and  edoxaban.
Apixaban  seems  less  affected  based  on
pharmacokinetics studies.
Bleeding  risk  and  bleeding-related  death
were  increased  significantly  in  these
population compared to warfarin
NB: AHA, ACC, HRS and EHRA guidelines all
refrained from supporting use of dabigatran,
rivaroxaban and edoxaban in patients with
chronic kidney disease (CKD) or on dialysis.
Only  warfarin  and  apixaban  seems  to  be
safer in these populations.
If  done,  plasma  DOAC
concentrations should be
measured a trough, just
before  the  next  pill  or
capsule intake after 5 or
more  intake  to  ensure
the  DOAC  has  reached
its steady state.
Plasma  DOAC
concentration  should  be
in  the  range  of
concentrations  observed
in other populations.
Post-hoc  analyses  from
phase-3  clinical  trials  and
post-marketing observational
studies.
NB: Data are lacking to show
the  benefit  of  adjusting  the
dose based on individual PK
evaluation,  but  these  data
suggest  that  the  optimal




s  with  high
bleeding risk
To  be  on  the  safe  side,  intervention
categorized as being at  high bleeding risk
should  be  done  in  patients  with  no  or
undetectable DOAC concentration. 
Using the PK approach would not ensure all
patients  will  have  cleared  completely  the
DOAC  as  many  variables  could  interfere
with the elimination of DOACs. As some of
the factors used to set up the PK approach
also  relies  on  surrogate  biomarkers  (e.g.
serum creatinine or liver function), the most
obvious and rationale solution could be the
measurement of DOAC concentrations.
Plasma  DOAC
concentration  should  be
measured within the few
hours  before  the
intervention and planned
surgical  intervention
should  proceed  when
the  level  is  considered
low enough.
Plasma  DOAC
concentration  should  be





NB:  there  are  currently  no
prospectively  validated  data
with  hard  clinical  endpoints
on  cut-off  values  of  any
coagulation test to guide the




For  patient with BMI above 40 kg/m2,  if  a
DOAC  is  chosen,  obtaining  a  peak  and
trough  DOAC  concentration  estimate  after
at  least  5  doses  may  be  of  interest  to
ensure  the  plasm  concentrations  are
roughly within the range published for other
patients
NB:  It  remains  unclear  whether  adequate
DOAC  concentrations  are  achieved  to  be
clinically effective. The majority of post-hoc
analyses  showed  reassuring  data  for
patients up to 40 kg/m2 but further data are
needed in extreme obese.
If  done,  plasma  DOAC
concentrations should be
measured at trough, just
before  the  next  pill  or
capsule  intake  and  at
peak  after  5  or  more
intakes  to  ensure  the
DOAC  has  reached  its
steady state.
Plasma  DOAC
concentration  should  be
in  the  range  of
concentrations  observed
in other populations.




Numerous  drug  interactions  have  been
described  and  investigated  by  the
manufacturers,  sometimes  requiring  dose
adaptations.
However, unknown drug interactions as well
as multiple drug interactions may interfere
with  drug  levels  to  a  degree  which  may
If  done,  plasma  DOAC
concentrations should be
measured at trough, just
before  the  next  pill  or
capsule intake after 5 or
more  intakes  to  ensure
the  DOAC  has  reached
Pharmacokinetic  studies,














































































have a clinical relevance. Evaluating DOAC




concentration  should  be
in  the  range  of
concentrations  observed
in other populations.













Measuring  the anticoagulant  effects  or
plasma drug  levels  of  DOAC  can  help
determine their contribution to bleeding
or  to  determine  when  it  is  safe  to
perform  an  urgent  or  unplanned
intervention.
Assessing potential rebound effect after
administration of reversal agents
NB:  Delaying  antidote  administration
until  coagulation  test  results  are
available may be detrimental in DOAC-
treated  patients  with  life-threatening
bleeding,  such  as  intracranial  bleeding
or in those requiring emergency surgery
for life-threatening conditions such as a
ruptured aortic aneurysm.
Measurement  of  plasma
DOAC  concentration




are  based  on  plasma
DOAC  concentrations.  In
patients  with  serious
bleeding,  a  DOAC
concentration > 50 ng/mL
is  considered  sufficiently
high  to  warrant  antidote
administration whereas in
those requiring an urgent
intervention  associated
with  a  high  risk  of
bleeding,  antidote
administration  should  be
considered  if  the  DOAC
concentration exceeds 30
ng/mL.
Case  series  and  expert
opinions.
Post-hoc analyses from phase-
3 clinical trials and case series.
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